Litcius/Paper detail

LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)

Sherene Loi, Giuseppe Curigliano, Roberto Salgado, Roberto Iván Romero Díaz, Suzette Delaloge, C. Rojas, Marleen Kok, C. Saura Manich, Nadia Harbeck, Elizabeth A. Mittendorf, Denise A. Yardley, Lajos Pusztai, Alberto Suárez Zaizar, Aurelian Ungureanu, Felipe Ades, R. Chandra, Raheel Nathani, Misena Pacius, Jintong Wu, Heather L. McArthur

2023Annals of Oncology103 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOncologyInternal medicineNivolumabChemotherapyAdjuvantNeoadjuvant therapyCancerBreast cancerImmunotherapyCancer Immunotherapy and BiomarkersBreast Cancer Treatment StudiesHER2/EGFR in Cancer Research